Mobile

The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels when it is given with Gemcitabine. We want to find out what effects, good and/or bad, GS-6624 has ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-003753-26

The purpose of this study is to test the effectiveness and safety of GS-6624 at different dose levels when it is given with Gemcitabine. We want to find out what effects, good and/or bad, GS-6624 has on you and your metastatic pancreatic adenocarcinoma when it is given with Gemcitabine. Gemcitabine is approved by the FDA for metastatic pancreatic adenocarcinoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the additive efficacy of GS-6624 vs. placebo in combination with gemcitabine as measured by improvement in progression free survival (PFS)

Critère d'inclusion

  • Metastatic Pancreatic Adenocarcinoma

Liens